B of A Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $85

Benzinga · 01/07 17:50
B of A Securities analyst Geoff Meacham maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $98 to $85.